Dascena’s InSight system improves sepsis outcomes at Nacogdoches Memorial Hospital

Jul 2 2018

Dascena, Inc. announces improved patient outcomes at Nacogdoches Memorial Hospital with the implementation InSight, a machine learning based algorithm for sepsis treatment. The introduction of InSight led to sepsis related mortality falling 9.85% and a hospital length of stay reduction of 12.4%, compared to baseline.

Nacogdoches Memorial Hospital (NMH) is a community hospital located in Eastern Texas. It is the only hospital in Deep East Texas to have Joint Commission-certified stroke centers, a Level III trauma center and NICU, and a standalone inpatient rehabilitation center.

InSight, developed by Dascena, predicts the onset of sepsis using only patient vital signs available in the EHR, improving the detection of sepsis and the timing of treatment administration.

Seeking to improve patient outcomes and adopt new technologies, NMH decided to focus on sepsis treatment and implement InSight hospital wide, including the emergency department, intensive care units, intermediate care units, floor units, and rehabilitation center. In collaboration with Dascena’s onboarding team, NMH staff created an alert system for InSight to immediately notify staff on duty of early predictions of sepsis onset. In addition, Dascena’s onboarding team and the NMH leadership team worked to provide hospital staff with the latest information on sepsis care management.

Prior to the implementation of InSight, NMH clinicians relied on manual screening of patients. Now, with InSight, NMH clinicians are able to detect sepsis before onset and treat it early, leading to better patient outcomes. In the analysis of InSight outcome data, only adult patients that met at least two SIRS criteria were included. Baseline outcomes (October 1-31, 2017, n=39) were calculated and compared to post-InSight implementation (November 1, 2017 - March 31, 2018, n=297).

“We are thrilled that Nacogdoches Memorial Hospital was able to provide better care for their patients with the use of InSight,” said Ritankar Das, CEO of Dascena. “Dascena will continue to work with NMH to ensure patients receive the full benefit of our algorithm-driven approach.”